Interpretation of research and innovation part of the WHO Global Tuberculosis Report 2025

doi:10.19982/j.issn.1000-6621.20250507

Abstract

Abstract:

Technological innovation is pivotal to curbing the tuberculosis (TB) epidemic through sustained research and development. On Nov 12, 2025, World Health Organization released the Global Tuberculosis Report 2025. This paper reviews the key achievements in the areas of TB research and innovation for new diagnostics, drugs, and regimens as well as vaccines introduced in the report, and discusses some of China’s indigenous progresses in related areas. The authors aim to make China’s TB professionals better informed about the latest research development in TB prevention and control around the globe, fostering indigenous TB innovation efforts with greater originality.

Key words: Tuberculosis, Research, Benchmarking, Comment

CLC Number:

Shu Wei, Liu Yuhong. Interpretation of research and innovation part of the WHO Global Tuberculosis Report 2025[J]. Chinese Journal of Antituberculosis, 2026, 48(3): 307-312. doi: 10.19982/j.issn.1000-6621.20250507

References 15

[1]	屈燕, 李涛, 马文斌, 等世界卫生组织《2025年全球结核病报告》解读. 结核与肺部疾病杂志, 2025, 6(6): 613-623. doi:10.19983/j.issn.2096-8493.20250178.
[2]	World Health Organization. Moscow Declaration to End TB; First WHO global ministerial conference on ending TB in the sustainable development era: a multisectoral response. Geneva: World Health Organization and the Ministry of Health of the Russian Federation, 2017.
[3]	World Health Organization. The Global Strategy for TB research and innovation. Geneva: World Health Organization, 2020.
[4]	General Assembly of the United Nations. Political declaration of the high-level meeting of the General Assembly on the fight against tuberculosis. New York: United Nations, 2018.
[5]	General Assembly of the United Nations. litical declaration of the high-level meeting of the General Assembly on the fight against tuberculosis. New York: United Nations, 2023.
[6]	Vachaspathi TD. Tuberculosis Diagnostics. New York: Treatment Action Group, 2025.
[7]	World Health Organization. WHO consolidated guidelines on tuberculosis: module 4: treatment and care. Geneva: World Health Organization, 2025.
[8]	McKenna L. Tuberculosis Treatment. New York: Treatment Action Group, 2025.
[9]	Guglielmetti L, Khan U, Velásquez GE, et al. Bedaquiline, delamanid, linezolid, and clofazimine for rifampicin-resistant and fluoroquinolone-resistant tuberculosis (endTB-Q): an open-label, multicentre, stratified, non-inferiority, randomised, controlled, phase 3 trial. Lancet Respir Med, 2025, 13(9):809-820. doi:10.1016/S2213-2600(25)00194-8. URL pmid: 40683298
[10]	Saukkonen JJ, Duarte R, Munsiff SS, et al. Updates on the Treatment of Drug-Susceptible and Drug-Resistant Tuberculosis: An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline. Am J Respir Crit Care Med, 2025, 211(1):15-33. doi:10.1164/rccm.202410-2096ST.
[11]	Heinrich N, Manyama C, Koele SE, et al. Sutezolid in com-bination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-SUDOCU-01): a prospective, open-label, randomised, phase 2b dose-finding trial. Lancet Infect Dis, 2025, 25(11):1208-1218. doi:10.1016/S1473-3099(25)00213-0. URL pmid: 40645196
[12]	Minja LT, van der Feltz I, Manyama C, et al. Delpazolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-DECODE-01): a prospective, randomised, open-label, phase 2b, dose-finding trial. Lancet Infect Dis, 2025, 25(11):1219-1229. doi:10.1016/S1473-3099(25)00289-0. URL pmid: 40645198
[13]	Metcalfe JZ, Weir IR, Scarsi KK, et al. A 3-month clofazimine-rifapentine-containing regimen for drug-susceptible tuberculosis versus standard of care (Clo-Fast): a randomised, open-label, phase 2c clinical trial. Lancet Infect Dis, 2026, 26(1):46-54. doi:10.1016/S1473-3099(25)00436-0.
[14]	Paton NI, Cousins C, Sari IP, et al. Efficacy and safety of 8-week regimens for the treatment of rifampicin-susceptible pulmonary tuberculosis (TRUNCATE-TB): a prespecified exploratory analysis of a multi-arm, multi-stage, open-label, randomised controlled trial. Lancet Infect Dis, 2025, 25(10):1084-1096. doi:10.1016/S1473-3099(25)00151-3. URL pmid: 40414233
[15]	王歆尧, 姜美丽, 庞元捷, 等. 全球结核病疫苗研发进展. 中华流行病学杂志, 2025, 46(8):1473-1479. doi:10.3760/cma.j.cn112338-20241217-00806.